-
Dr. Reddy's Laboratories records $2.2 billion in annual sales, up 14%
HYDERABAD, India — Dr. Reddy’s Laboratories on Tuesday posted $2.2 billion in annual sales for the fiscal year ended March 31, representing growth of 14%.
The company launched 54 new generic products and filed 51 new product registrations and 61 Drug Master Files globally in fiscal year 2014.
-
Actavis gains FDA approval for generic version of Mallinckrodt's Exalgo
DUBLIN — Actavis on Tuesday announced that it has received final approval from the Food and Drug Administration on its abbreviated new drug application for a generic version of Mallinckrodt's Exalgo (hydromorphone hydrochloride extended-release tablets 8 mg, 12 mg and 16 mg).
Actavis intends to begin shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity, the company stated.